LANCASTER, Penn. & SEATTLE – Skipta, the leading social network of specialized online medical communities for verified healthcare professionals, including Oncology Nation, Psychiatrist Connect and Doctor Unite, recently announced its partnership with new media company, The Fresh Toast, to provide trusted, reliable information on cannabinoid medicine. In a first for the cannabis industry, this partnership will provide guidelines and research information for the potential medicinal uses of cannabis to alleviate symptoms from identified diseases and illness. The Fresh Toast will serve as an exclusive media partner for news and information on cannabinoid medicine as authored by Skipta or its members.
The Fresh Toast, a daily lifestyle and entertainment site with a side of cannabis, launched in October 2016 and is the first cannabis site to have mainstream appeal. The number of visitors to TheFreshToast.com has quickly grown, outpacing most competitors, with 25 percent of readers returning for multiple visits per day. Unlike other cannabis sites, The Fresh Toast has a large number of female readers with a 43/57 female/male mix. The Fresh Toast is expanding its North American syndication newspaper and magazine relationships, including the NY Daily News, Men’s Health and Salon.
Currently 29 states, including Florida, North Dakota, Connecticut, Massachusetts, Arkansas, Arizona and the District of Columbia, allow medical cannabis. In 2016, cannabis was a $7.1 billion-dollar industry with over 100,000 people employed in the United States. Studies show an estimated 42,000,000 annual U.S. consumers. According to the New England Journal of Medicine, 76% of doctors are in favor of the use of cannabis for medicinal purposes.
“As we see growing acceptance of cannabis in the U.S., especially for medical use, it is important for reliable health organizations and reputable media to take leadership in providing the public with scientifically sound information,” stated Regina Benjamin, former United States surgeon general.
A key section of The Fresh Toast is the Rx overseen by Tom Green, MD. As the first site with a continuum of care, the site’s goal is providing knowledge in an understandable and familiar format allowing patients and caregivers to learn about the diseases that could benefit from the use of cannabinoid medicine and their potential treatment options. The site is investing in expanding health coverage and sharing patient stories to give a full picture of the pluses and minuses.
“There’s certainly demand for high-quality and trustworthy cannabis information. People want to get it from a publisher they trust,” said Christian Hendricks, a board member of The Fresh Toast and well-known media executive.
“The partnership between The Fresh Toast and Skipta can be a transformational step forward for medical cannabis. The Fresh Toast is one of the leading voices on all things cannabis and, by forging a relationship with a massive network of healthcare professionals, it will increase information, knowledge, and access to knowledge for those at the forefront of the medical cannabis conversation. Relationships like this one help fill a government-driven, gaping void in our understanding of medical cannabis and the realities of its practice in American society,” said John Hudak, Ph.D., senior fellow in governance studies at the Brookings Institution and author of Marijuana: A Short History.
“We are proud to work with the Skipta team of medical professionals,” said JJ McKay, founder/publisher of The Fresh Toast. “With 40 percent of our readership coming from red states, I believe we offer a vehicle to reach the general public. With proper use, cannabinoid medicine can help tens of millions of people. With national leaders like Sanjay Gupta and Senator Orrin Hatch endorsing medical cannabis, we are honored to work with Skipta to help improve people’s lives.”
Skipta Founder and CEO, Dr. Theodore Search, Pharm.D., stated, “This exciting partnership with The Fresh Toast offers us a unique vehicle to distribute reliable, trusted information on a potential treatment option likely to become revolutionary in improving patient outcomes across a variety of therapeutic areas. With clinicaltrials.gov currently citing more than 700 studies regarding the use of cannabinoid medicine across various phases of the clinical process, there is much information out there for the public to stay apprised of; we are proud to lighten that burden by bringing the latest news and information to the public from a trusted source.”
Courtesy of The Cannabis Story Lab